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a b s t r a c t 
Hepatocellular carcinoma (HCC) is one of the deadliest cancers due to its complexities, reoc- 
currence after surgical resection, metastasis and heterogeneity. In addition to sorafenib and 
lenvatinib for the treatment of HCC approved by FDA, various strategies including transar- 
terial chemoembolization, radiotherapy, locoregional therapy and chemotherapy have been 
investigated in clinics. Recently, cancer nanotechnology has got great attention for the treat- 
ment of various cancers including HCC. Both passive and active targetings are progressing 
at a steady rate. Herein, we describe the lessons learned from pathogenesis of HCC and the 
understanding of targeted and non-targeted nanoparticles used for the delivery of small 
molecules, monoclonal antibodies, miRNAs and peptides. Exploring current efficacy is to en- 
hance tumor cell response of chemotherapy. It highlights the opportunities and challenges 
faced by nanotechnologies in contemporary hepatocellular carcinoma therapy, where per- 
sonalized medicine is increasingly becoming the mainstay. Overall objective of this review is 
to enhance our understanding in the design and development of nanotechnology for treat- 
ment of HCC. 
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1. Introduction 
Hepatocellular carcinoma (HCC) is the sixth most malignant 
human cancer and rank third in cancer-related deaths globally 
among cancer patients. The incidence also is geographically 
related, as is the mortality, with Eastern and South-Eastern 
Asia and Western Africa having a high incidence [1–3] . HCC 
usually occurs in the established background of liver cirrhosis- 
due to the endopathic cause and exopathic cause often varies 
considerably across areas and populations. Normally, HCC can 
be treated curatively with surgical resection or liver transplan- 
tation if diagnosed early [4] . However, since the majority of 
HCC patients are diagnosed at an advanced stage, their me- 
dian survival times are generally less than 1 year, leading to 
a poor prognosis [5] . One reason is surveillance programs are 
not widely implemented, despite being recommended in na- 
tional guidelines [6] . On the other hand, prevention of alcohol 
intake, vaccination against hepatitis B virus (HBV) infection, 
intake of vitamin D and calcium can prevent HCC in many 
cases [7] . However, they could not be used to obliterate the dis- 
ease. Furthermore, many investigations have shown that the 
occurrence of this multi-stage carcinogenesis evolves through 
dysregulation of multiple signaling pathways, genetic alter- 
ations with the initiation of inflammatory responses lead- 
ing to the formation of a heterogeneous solid tumorous mass 
[8] . Implementation of such programs has only resulted in an 
early diagnosis in some rich places [9] . 
To date, there are six treatments can extend life expectancy 
of patients with HCC: surgical resection, liver transplantation, 
radiofrequency ablation, transcatheter arterial chemoem- 
bolization (TACE), sorafenib and lenvatinib [10,11] . One 
third of patients are eligible for potentially curative therapies, 
which include resection, transplantation or local ablation, and 
such curative treatment can extend median survival times 
beyond 60 months [12] . Unfortunately, most patients are still 
diagnosed at advanced disease stages. In this setting, only 
treatment with sorafenib (the first FDA approved molecularly 
targeted drug for HCC treatment) is able to improve overall 
survival in the last few decades [13] . In 2018, lenvatinib- 
capsules (Lenvima, Eisai Inc.) was approved by FDA for the 
first-line treatment of un-resectable hepatocellular carcinoma 
and showed better subordinate clinical endpoints when com- 
pared with sorafenib [14] .Although the anti-cancer potency of 
sorafenib, lenvatinib and some other drugs have been proven, 
poor aqueous solubility, pharmacokinetics and undesirable 
side effects make the approach difficult to apply widely in 
HCC patients [15] . The major side effects of these drugs treat- 
ment are elevated blood pressure, diarrhea, fatigue, hand-foot 
syndrome, skin rash/desquamation, and nausea [16] . The 
poor aqueous solubility and side effects might be overcome 
by the use of nanotechnologies that can control and target 
the release of effective drugs to the specific tumor site [17] . 
With increasing numbers of nanotherapeutics and nan- 
odiagnostics being commercialized or having reached clinical 
stage in recent years [18] . Plenty of drug delivery vehicles have 
been developed from different biomaterials, such as synthetic 
polymers [19–24] , natural polymers [25–28] , microsphere 
liposomes [29–31] , peptide [32–36] , small molecules [37–41] , 
and protein [42–46] et al. Specific cancer nanotechnologies 
have been proven to be efficacious with respect to better 
targeting and minimizing the non-specific cytotoxic effect to 
the surrounding organs [47–51] . Targeting the receptors by 
drug delivery nanoparticles could significantly alleviate the 
adversities of chemotherapy [52,53] . Significant achievements 
also have been witnessed in the field of HCC drug delivery sys- 
tems [52,54,55] . Understanding the biological processes of the 
distribution or/and retention of nanoparticles inside the HCC 
microenvironment is therefore essential to the development 
of personalized nanomedicine approaches. Herein, we exam- 
ine the fundamentals behind targeting of nanoparticles to 
HCC and cancer cells. We will discuss the causes and recent 
treatment modalities of HCC, with an emphasis on can- 
cer nanotechnology for enhancing HCC cell response to 
chemotherapy. With the perspective of developing new ther- 
apeutic nanotechnologies, we will also examine how the 
physicochemical parameters of the nanoparticles affect their 
localization, retention, cell binding, internalization, efficacy 
and toxicity. 
2. Current treatment strategies for 
hepatocellular carcinoma 
HCC has been well investigated as a complex multi-step 
process arising from combination of genetic and epigenetic 
alterations, somatic mutations, genomic instability and 
environmental factors [56] . There are multiple factors re- 
sponsible for the initiation and progression of HCC including 
virus-induced [56,57] , alcohol-induced, fungi-induced obesity 
and type II diabetes [58,59] . Common treatment strategies are 
composed of surgical (resection and liver transplantation) and 
nonsurgical approaches (transarterial chemoembolization, 
transartetial radiation, percutaneous local ablation, mi- 
crowave ablation and systemic therapy). In nonsurgical drug 
therapy, not only small molecule drugs such as sorafenib and 
lenvatinib, but also gene therapy, immunotherapy and com- 
bination therapies have been used for HCC therapy [60–62] . 
Among them, systemic therapies which using small molecule 
drugs to target various signaling pathways following surgical 
resection and liver transplantation have been applied partic- 
ularly where locoregional therapy has been confirmed invalid 
[59,63] . However, small molecular chemotherapy in HCC 
also suffers from the drawbacks of dose-limiting toxicities, 
development of multidrug resistance (MDR) and unfavorable 
side-effects like other cancers [64–67] . Although various 
multikinase inhibitors have been used for systemic treatment 
of HCC, only few drugs such as sorafenib (orally active multi- 
kinase inhibitor) and lenvatinib (oral multi-targeted tyrosine 
kinase inhibitor) have been approved as deserves special 
mention drug for treatment of advanced HCC. Many investi- 
gations have indicated that it could prolong overall survival in 
patients and delay the time to progression of advanced HCC 
by using sorafenib or lenvatinib. However, fatigue, diarrhea, 
hypertension, skin toxicity, weight loss, hypophosphatemia 
are almost the frequent symptoms amongst patients with 
these two drugs’ treatment. Further, various first line and sec- 
ond line therapies are currently under evaluation for the HCC 
treatment, however, potential randomized trial with another 
drugs such as sunitinib, tivantinib, brivanib and linifanib have 
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been disappointing due to the adverse effects and not supe- 
rior to sorafenib. Only lenvatinib capsules (Lenvima, Eisai Inc.) 
have been demonstrated that were noninferior than sorafenib 
for overall survival. In view of the failures of clinical trials for 
most of the chemotherapeutics drugs, elaborate and exten- 
sive information of the underlying molecular mechanisms 
undergoing in each patient’s tumor progression is critically 
necessary. Other small molecule targeted therapies such as 
regorafenib, doxorubicin, gefitinib, vatalanib, cediranib, borte- 
zomib (proteasome inhibitor), rapamycin, sirolimus, and gem- 
citabine as single agent or in combination with mAb have been 
evaluated in clinical trials targeting pathways which are acti- 
vated in HCC. Recently, combination therapies also have been 
widely studies and shown many positive results [65,68,69] . 
In addition, two other types of molecular-based therapies 
are currently under development for the treatment of HCC: 
epigenetic modifying therapies [70] and microRNAs (miRNAs) 
[71] . Epigenetic modifications in certain genes have been 
proposed to drive progression of HCC. Therapies targeting 
epigenetic modifiers, such as DNA methyltransferases and 
histone deacetylases, are attractive approaches [72,73] . A mul- 
ticenter phase I/II trial of the histone deacetylase inhibitor 
belinostat for treatment of patients with HCC is currently 
being developed [74] . Some other researches also showed that 
those with high immunoreactivity to the UV excision repair 
protein RAD23 homologue B (HR23B) to HDAC inhibitors had a 
higher rate of disease stabilization [75] . Bitzer et al. have stud- 
ied the resminostat plus sorafenib as the second line therapy 
and showed potential activity in patients with HCC [76] . 
MiRNAs-based strategies that block the interaction of HDAC 
with its substrates have also been studies [77–79] . The results 
showed that many kinds of miRNAs are important regulators 
of gene expression and associated with the development of 
HCC [80,81] . 
Otherwise, their value in clinical management has been 
investigated. Functional screens of miRNAs have identified 
key regulators of glypican-3, a surface proteoglycan that acts 
as a co-receptor, controls cell apoptosis, proliferation and is 
a potential target for treatment of HCC [78] . In a word, evi- 
dence suggests that miRNA-based therapies are worthwhile 
approaches to cancer treatment. Shuai and his co-workers 
have investigated the folate-targeted theranosticsiRNA (Fa- 
PEG-gPEI-SPION/psiRNA-TBLR1) nanoparticles for enhanced 
HCC chemotherapy and obtained the positive results ( Fig. 4 ). 
Recently, cancer immunotherapy rises rapidly and also 
plays a critical role in HCC treatment due to the liver as the 
mainimmune organ of the lymphatic system [79,82,83] . Three 
kinds of hepatic cells named liver sinusoidal endothelial cells, 
Kupffer cells and dendritic cells (DCs) are main roles for the 
immune response in the HCC microenvironment [84] . How- 
ever, only few immunotherapy trials for HCC have been stud- 
ied so far with contrasting results, suggesting that significant 
improvements are needed. It is beyond a doubt that such an 
inherent immune tumor environment needs to be taken into 
account and counterbalanced when immunotherapeutic ap- 
proaches are designed and implemented in HCC. Therefore, 
combination therapy of monoclonal antibodies or chemother- 
apies along with transarterial chemoembolization is a promis- 
ing approach in increasing the overall survival of HCC patients 
whose chances of relapse after surgery are evident [85,86] . Pre- 
vious studies have shown promising safety, efficacy and tumor 
targeting of the 131I-labeled metuximab and transcatheter ar- 
terial chemoembolization combination for unresectable HCC 
[87,88] . Combination of low dose cyclophosphamide treat- 
ment with a vaccine ( e.g. telomerase vaccine) in HCC has been 
evaluated in a single clinical trial [89,90] . Unfortunately, the 
combination did not show antitumor efficacy in respect to tu- 
mor response and time to progression. Nearly 5 years, PD-1 
and its ligand PD-L1 have been widely used as an immune reg- 
ulating checkpoint with a well-established role in the devel- 
opment of HCC progression. A single clinical trial in HCC pa- 
tients has been reported combining anti-PD-1 Ab and a GPC3 
peptide vaccine. Results showed improved antitumor effects 
of a peptide vaccine correlating with the increased levels of 
vaccine-specific CTLs and reduced tumor-infiltrating T cells 
[88] . Nivolumab is an immunotherapy that inhibits PD-1.It has 
been used as a second line systemic treatment in HCC patients 
who have been treated with or intolerant to sorafenib and has 
been granted approval by FDA in 2017. To increase responses 
to immunotherapy, combination of PD-1 or PDL1 and tyro- 
sine kinase inhibitors are currently investigated significant 
improved clinical outcomes. Xu et al. generated and used SHR- 
1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) to 
study combination therapy treatment with advanced HCC. It 
was found that combination therapy demonstrated manage- 
able toxicity and encouraging clinical activityin patients [91] . 
Markus Joerger et al. also provided data from this clinical case 
to support the potential of combination treatment of the oral 
multi-kinase inhibitor regorafenib with PD-1 or PDL1 targeted 
monoclonal antibodies to advanced HCC therapy [92] . These 
discoveries can be used to promote the development of HCC 
immunotherapy. After the completion of genome-wide asso- 
ciation studies (GWAS) and pharmacogenomics, personalized 
medicine has gradually become possible in HCC. Personalized 
medicine has been the mainstay for the treatment of HCC. Per- 
sonal genetic analysis can hold the promise of identifying pa- 
tients and family members, who would benefit from person- 
alized medicine, modifying risk factors and so on [93,94] . 
3. Application of nanomedicine for 
hepatocellular carcinoma therapy 
Although the efficiency of these few chemotherapeutics 
molecules in the management of HCC, the drugs are not usu- 
ally delivered at high concentrations into the malignant tis- 
sues. Thereby, hydrophobicity, toxicity and bioavailability of 
these small molecular drugs caused dose-limiting side ef- 
fects are still the deliver challenge. Nanotechnology is a pow- 
erful tool for the delivery and targeting of therapeutics in 
HCC [95–97] . Since HCC cells undergo genetic and pheno- 
typic changes compared to other hepatic cells, targeting of 
HCC cells is an obvious avenue for treatment of HCC ( Fig. 1 ). 
Various targeting and delivery strategies have been explored 
for nanoparticles (NPs) [98–100] , micelles [101,102] , liposomes 
[103] both passively and receptor-mediated active targeting in 
HCC. Normally, nanotechnologies could overcome the unfa- 
vorable side-effects of systemic administration of chemother- 
apeutics by improving the pharmacokinetics, biodistribution, 
accumulating cytotoxic agents in tumor site and elevating 
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Fig. 1 – This diagram summarizes known therapies for treatment of HCC receptors, and the cellular locations of drug-target 
interactions. 
the effectiveness of treatment through drug delivery nanosys- 
tems [104–107] . Nanometer size range of nanosystems could 
help drugs reach the tumor cells through the leaky vascula- 
ture and enhance site-specific enhanced delivery [108] . How- 
ever, degradability, stability, circulation,metabolismas well as 
the balance between side effects and curative effect still 
have to be carefully considered for the design of efficient de- 
liver nanosystems. Otherwise, HCC patients almost developed 
based on prolonged inflammatory processes, which emerged 
as a result of genetic and epigenetic alterations. Tumor sup- 
pressor genes, in particular p53 and retinoblastoma, are the 
frequently altered in HCC. Further, as a kind of highly vas- 
cular tissues, HCC progression is almost accompanied by 
abnormal angiogenesis at different stage and etiology. 
Thereby, angiogenesis related molecules such as VEGFR, RAF 
and EGFR are extremely useful targets in the development of 
selective therapeutics. Hence, the specific surface molecules 
of liver cells including ASGPR and endocytic cell surface recep- 
tors are highly expressed by HCC cells that are distinguished 
from other tissues. These specific related genotypic and phe- 
notypic alterations have been utilized for HCC targeting di- 
agnosis and therapy. Herein, some of the recent designs and 
findings in the field of nano-based medicines for passive and 
receptor-specific active targeting for the treatment of hepato- 
cellular carcinogenesis would be discussed. 
3.1. Passive targeting nanotechnology for hepatocellular 
carcinoma therapy 
In case of passive targeting, nanomedicines can reach tumor 
via the leaky vasculature of the tumors by the enhanced per- 
meability and retention (EPR) effect [109–111] . Nanoparticles 
can be delivered to specific sites by passive targeting. It also 
has been reported that nanoparticles injected intravenously 
are taken up by the liver after only a few minutes due to the 
opsonization process. To date, various stimuli including pH, 
enzymatic, redox, light and heat have been used for passive 
targeting of nanoparticles carrying drugs in HCC [112,113] . Re- 
cently, nanoassemblies based on supramolecular complexes 
of nonionic amphiphiliccyclodextrin and sorafenib as effec- 
tive weapons to kill HCC cells have been developed ( Fig. 2 ) 
[114] . Sorafenib robustly interacts with nonionic amphiphilic- 
cyclodextrin, forming supramolecular complexes that be- 
have as building passive targeting nanoassemblies. These 
nanoassemblies are highly stable in aqueous medium, retain- 
ing sorafenib up to 2 weeks. Interestingly, these passive target- 
ing systems show very low hemolytic activity and a high effi- 
ciency to inhibit the growth of three different HCC cell lines, 
similarly to free sorafenib, which indicated the preferential in 
vivo accumulation of nanoassemblies could result in a supe- 
rior therapeutic efficacy than the free drug.Antisense-miRNA- 
21 and gemcitabine (GEM) co-encapsulated PEGylated-PLGA 
NPs have been developed to overcome drug resistance and im- 
prove their therapeutic efficacy in vitro . For lenvatinib, Yuan 
et al. have developed aliposome-encapsulated contrast agent 
comprising lenvatinib-bound nanoparticles for screening of 
early–phase non–small cell lung cancer. However, nanotech- 
nology has not been used for enhancing the HCC therapy of 
lenvatinib. 
3.2. Active targeting nanotechnology for hepatocellular 
carcinoma therapy 
Although nanosystems have gained tremendous success for 
delivering chemotherapeutic agents, their rapid clearance by 
the reticuloendothelial system (RES) after systemic adminis- 
tration restricts them from their delivery to hepatocytes which 
are the main site for HCC origination [115,116] . As a result, 
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Fig. 2 – Sketched view of nanoassemblies formation in aqueous solution (Reproduced with permission from [67] . Copyright 
2017 Shenyang Pharmaceutical University). 
the nanotechnological approaches of site specific and/or tar- 
geted drug delivery amenable to distinct hepatic cells and 
their receptors are being studied extensively by researchers 
[117–119] . Further, active targeting was almost accompanied 
with passive targeting when nanosystems were designed 
[120–122] . 
Asialoglycoprotein receptor (ASGPR) has been identified 
as a commonly found lectin receptor which is profoundly 
expressed in mammalian liver cells [123,124] . Using natural 
ligands such as asialofeutin as well as synthetic ligands 
could achieve specific liver ASGPR targeting [58] . For example, 
nanoparticles and liposomes incorporating various lactosy- 
lated strategies have been evaluated for targeting efficacy to 
hepatic tumor cells. Polyethylene sebacate (PES)-Gantrez®
AN 119 Dox NPs have been developed with ASGPR ligands 
by Sandhya et al. and showed the high efficacy coupled 
with greater safety as a promising nanocarrier for improved 
therapy of HCC [125] . Meng and colleagues successfully 
demonstrated the galactose-installed photo-crosslinked pH- 
sensitive degradable micelles (Gal-CLMs) for active targeting 
chemotherapy have a great potential for hepatocellular carci- 
noma chemotherapy ( Fig. 3 ) [126] . In another study, cholesterol 
arabinogalactan anchored liposomes (CHOL-Al-AG) carrying 
DOX targeting ASGPR receptors on mammalian hepatocytes 
in HCC were studied where improved delivery of DOX was 
reported in terms of stability, loading efficiency, tumor re- 
gression both in vitro and in vivo compared to unmodified 
liposomes [127] . 
Integrins are transmembrane receptors which are respon- 
sible for cell–cell and cell-extracellular matrix interactions 
[128] . Hepatic stellate cells almost express integrins when 
it suffers fibrotic liver [129] . For instance, the peptide se- 
quence RGD acts as a targeting ligand for collagen VI and 
RGD-coupled liposomes has been extensively applied for 
targeting integrin receptors in HCC [130] . To deliver the poor 
water soluble drug paclitaxel (PTX) effectively in HCC, Chen et 
al. have developed a kind of integrin- αv β3 receptor targeted 
liposomal PTX [131] . RGD-motif was successfully conjugated 
to DSPE-PEG to prepare RGD-modified liposomes (RGD-LP). 
Both in vitro and in vivo studies demonstrated RGD-LP-PTX 
had enhanced anti-proliferative and tumor growth inhibitory 
effects activity against HepG2 cells and HepG2-bearing mice 
tumor respectively than RGD-LP or free PTX. Moreover, combi- 
nation of DOX and sorafenib in iRGD decorated lipid-polymer 
hybrid core-shell structured NPs also indicated enhanced 
antitumor efficacy in HCC in vivo models with improved 
bioavailability and longer circulation time [132] . Recently, 
RGD modified lipid-coated NPs for the co-delivery of the 
hydrophobic drugs have been used by Wang et al. to against 
hepatocellular carcinoma. The combination of sorafenib and 
quercetin formulations was more effective than the single 
drug formulations in both NPs and solution groups. This RGD 
modified NPs achieved the most significant tumor growth 
inhibition effect in vitro and in vivo [133] . 
Vandetanib is an oral inhibitor of VEGFR, EGFR, RET- 
tyrosine kinase and has been approved for medullary thyroid 
cancer [134] . It has been explored for HCC as encapsulated NPs 
with targeting moiety with enhanced antitumor efficacy [135] . 
HCC cells overexpressed transferrin (Tf) receptors which 
have become useful targeting avenues for potential treat- 
ment [136] . The ideal of sorafenib in albumin nano-shell 
was used and DOX was loaded in poly (vinyl alcohol) as 
nano-core, the interactions were simulated and then the 
nanomedicines were formed by a sequential freeze-thaw/ 
coacervation method ( Fig. 5 ) [137] . It indicated that ratio- 
nally designed core-shell nanoparticles can effectively com- 
bine clinically relevant single-agent drugs for exerting syner- 
gistic activity against liver cancer. 
CL4 RNA aptamer specific to EGFR and CD133 targeted ap- 
tamers was conjugated to PLGA nanoparticles was studied for 
salinomycin delivery to cancer stem cells in HCC treatment 
[138] . 
Like other cancers, folate receptors are significantly over- 
expressed in HCC and to target these receptors, its natu- 
ral ligand, folic acid (FA) has been explored for nanoparticle 
drug delivery to the cancer cells [3,139] . Xu et al. studied the 
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Fig. 3 – Illustration of pH-sensitive degradable micelles as an integrative nanovehicle for active targeting hepatocellular 
carcinoma chemotherapy (Reproduced with permission from [114] . Copyright 2015 American Chemical Society). 
antitumor potency of the folate receptor-targeted liposomes 
(FA-PEG-DSPE) co-delivery of antitumor agent docetaxel and 
iSur-pDNA in vitro and in vivo [140] . 
VEGF receptors are found to be overexpressed in HCC due 
to the receptor activation via multiple signaling pathways 
[140,141] . Recently, iRGD-decorated polymeric NPs for the ef- 
ficient delivery of vandetanib to HCC have been investigated. 
Wang et al. studied the biodegradable PEG-PLA to nanoprecip- 
itate this potent agent to form water-soluble NPs that are suit- 
able for intravenous administration [142] . Active targeting by 
aptamer-mediated delivery showed significant anti-tumor ef- 
ficacy when tested both in vitro and in vivo . The results also 
demonstrate that reformulating targeted therapeutic agents 
in NPs permits their systemic administration and thus signif- 
icantly improves the potency of currently available, orally de- 
livered agents. 
Glycyrrhetinic acid (GA) receptor is overexpressed on the 
hepatocyte surface and has been extensively studied for drug 
targeting [143] . Qi et al. reviewed the roles of this receptor 
and GA-mediated drug delivery in HCC [144] . GA-modified 
nanoparticles formulations of DOX exhibited a much higher 
level of tumor accumulation than nontargeted NPs at 1 h af- 
ter injection in hepatoma-bearing Balb/c mice. Zhang and col- 
leagues studied poly (L-Histidine) (PHIS) mediated polymeric 
system (GA-PEG-PHIS-PLGA) with GA for targeted delivery of 
the anti-cancer agent and rographolide [145] . 
Passive and active targeting nanotechnologies have shown 
some potential for hepatocellular carcinoma therapies. How- 
ever, tumor recurrence needs deeper or more thorough ther- 
apies, such as combination targeting, long circulation and so 
on. There are still many challenges for nanotechnology to fab- 
ricate more ideal delivery systems. 
4. Influence of the architecture of 
nanomedicine for hepatocellular carcinoma 
therapy 
The conjugation of ligands on the liver cells surface of 
nanosystems changes not only the properties of the targeting 
molecules but also the nanocarriers. From a chemical point 
of view, while ligands bind to the surface of NPs, it would 
lose the rotational and translational freedom bestowed to free 
molecules, otherwise, the new targeted entity achieves im- 
proved avidity due to the increased valency. Similarly, the size, 
shape, surface properties (charge, density and hydrophobic- 
ity), and composition of NPs can also be the influence fac- 
tors [146,147] . Fig. 6 shows the various properties of NPs which 
could change the delivery behavior of drugs from NPs to HCC 
cells. As we know, targeted NPs have shown benefits that go 
beyond the simple delivery of anti HCC drugs in many cases. 
To fully understand the properties of targeted NPs, it is impor- 
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Fig. 4 – Illustration of the folate-targeted theranostic small interfering RNA (siRNA) nanomedicine 
Fa-PEG-gPEI-SPION/psiRNA-TBLR1 hepatocellular carcinoma chemotherapy. 
tant to determine how the physicochemical properties of the 
NPs affect the interactions with their targets. Herein, we will 
discuss the main factors such as the ligand density, size and 
shape, surface and ligand charge and surface hydrophobicity 
of NPs to influence the behaviors of them. 
4.1. The ligand density 
For all delivery, the density of the targeting molecules on the 
surface of NPs impacts their affinity for the substrate due 
to increased cooperative effects. According to the thermody- 
namics, the more binding of a ligand to its substrate would 
promote the subsequent binding of its neighbors [148] . Bio- 
logically, increasing the ligand density would aggrandize the 
interactions of the NPs with the cell membrane so that force 
the local concentration of receptors and lead to internaliza- 
tion of cell membranes. These synergistic effects impede the 
detachment of the NPs from the cell surface and result in in- 
creased avidity [149] . 
The increasing ligand density usually results in improved 
cellular uptake in vitro [150] . However, targeting ligand density 
is critical to maximizing the efficiency of targeting NPs to 
cancer cells, and further increasing in ligand density will have 
deleterious effects on cell binding beyond the cooperative ef- 
fect of the ligand get saturate. The reason of this effect might 
due to the improper orientation of the ligand, steric hindrance 
of neighboring molecules or competitive behaviors for the 
binding of the receptor [151] . Similar negatively cooperative 
effect has been observed in ligand-clustered NPs where the 
ligands are arranged in patchy clusters by Hammond group 
[152] . Valencia et al. have investigated and showed that 
the use of high densities of hydrophobic ligands can in- 
crease the macrophage uptake of the NPs without providing 
significant advantages in terms of receptor-mediated inter- 
nalization [153] . 
Similar effects have been observed in vivo where higher 
densities do not always result in improved efficacy. Many stud- 
ies have shown that the alteration of the NPs surface to in- 
corporate the ligands can modify the blood circulation and 
biodistribution profiles of the NPs. Gu et al. have developed 
the aptamer-targeted polymeric NPs and shown that increas- 
ing the ligand density above 5% would cause the increasing 
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Fig. 5 – In silico docking simulation of core–shell nanomedicine (Reproduced with permission from [85] . Copyright 2016 Lin 
et al.). 
Fig. 6 – The physicochemical properties of the ligand and the NP affect their blood circulation profiles, their biodistribution 
and their ability to be internalized by cancer cells. 
clearance of the NPs by the liver and the spleen and impeded 
the distribution to the tumor [154] . 
Finally, many studies indicated that tumor selective an- 
tibodies could suffer from a binding-site barrier preventing 
their in-depth diffusion in the tumor [155,156] . This phe- 
nomenon is observed when high affinity molecules rapidly 
bind perivascular cells surrounding the cancer cells upon their 
extravasation to the tumor. The binding-site barrier also limits 
the in-depth diffusion of small molecular weight drugs with 
high affinity for HCC cells. This effect has been recently tar- 
geted to the receptors NPs which showed not enough HCC 
cells penetration compared to their non-targeted counterpart. 
Interestingly in that case, the binding-site barrier effect was 
not observed with larger NPs, presumably because of differ- 
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ences in the rates of HCC cells penetration and/or cell inter- 
nalization. Therefore, it seems probable that adequately tun- 
ing the ligand density on the NP surface could mitigate the 
binding-site barrier effect and translate into adequate reten- 
tion time and maximal cellular uptake throughout the HCC 
[157] . 
4.2. Size and shape 
The size and shape of the nanomaterial must be taken into 
consideration early in the design of targeted NPs. For HCC, 
smaller sizes and spherical shape represent higher curva- 
tures might promote hepatic targeting but can be problem- 
atic for post synthesis ligand functionalization. In addition, 
the tethering of high molecular weight ligands on the surface 
of NPs would increase their hydrodynamic radius [158] . This 
increase in size must always be considered in light of the pos- 
sible size restrictions involved in tumor accumulation. Besides 
the above mentioned effects, size can also affect cellular up- 
take. Although, the avidity of the particle increased with size 
range from 2 to 70 nm, the maximum uptake is a compromise 
between high avidity and optimal cell membrane wrapping 
around the NPs. Additionally, it is not clear how these conclu- 
sions can be expanded to other systems, as the interactions 
between NPs and cell highly-depend on the physicochemical 
properties of each material. In vivo , Lee et al. have reported that 
the size of actively targeted NPs could affect the intracellular 
deposition, not only in liver. In this case, although the intra- 
tumoral accumulation of smaller NPs was decreased due to 
shorter blood circulation times, the cytoplasmic and nuclear 
distribution of the 25-nm NPs was superior to that of the 60- 
nm colloids [158,159] . Moreover, the shape of NPs might in- 
fluence the cell uptake kinetics and internalization pathways 
through modulating the nanomaterial interact with the cell 
surface [160] . 
4.3. Surface and ligand charge 
Chemically, the charge of unfunctionalized NPs and that of 
the ligand can affect the conjugation yield and the spatial dis- 
play of the ligand on the surface. Repulsive or attractive forces 
between the surface of the NPs and the ligand can interfere 
with the conjugation or affect the final ligand structure and 
conformation. A chemical spacer with reasonable length, 
such as PEG, can be helpful to reduce the effect, but might 
simultaneously complicate synthesis and increase the final 
particle size [161,162] . Previous study also showed that the 
final surface charge will affect the efficacy of the targeted NPs 
[163] . For HCC, due to the interaction between cationic NPs 
and negatively charged cell membranes, positively-charged 
NPs show increased cellular binding and uptake, in a first pass 
effect and non-specific manner [164] . Because most ligands 
are charged molecules, the NPs surface charge is determined 
by the combinations of ligand densities, materials, NP for- 
mulation strategies and so on. Although recent work was 
carried out to address how charge density affects interactions 
of actively targeted NPs with HCC cells and NPs charge can 
affect cellular uptake, it remains unclear what parameters 
offer the best hepatic targeting in vivo . 
4.4. Surface hydrophobicity 
Except surface charge and above factors, hydrophobicity can 
also affect the architecture of the ligand display. Further, this 
property can have serious effects since most polymeric NPs 
have hydrophobic cores. Previous studies have shown that 
during the self-assembly of polymeric hydrophobic particles, 
hydrophobic ligand such as folic acid could remain trapped 
in the particle core without being properly displayed on the 
surface. In some cases, the final surface hydrophobicity of 
NPs can also affect nonspecific interactions with HCC cells. 
Actively targeted NPs without steric stabilization seem to 
lose their substrate-binding capacity when proteins adsorb on 
their surface. Surface functionalization can delay adsorption 
of plasma proteins and has been demonstrated in vitro and in 
vivo where the efficacy is dependent on both circulation times 
and ligand–substrate interactions. 
Overall, although the aforementioned factors hold true for 
the majority of therapeutic NPs, no general strategies have 
been found suitable to address the limitation of the nano- 
systems. For HCC therapy, assessing the efficacy of a treat- 
ment still requires time and resources, and providing match- 
ing targeted delivery nano-systems remain therefore unlikely. 
However, most studies have demonstrated the targeting lig- 
and might be key factor to decide the in vivo profiles of 
nanoparticles. More and more targeted liposomes and poly- 
meric NPs have been made to clinical development stages 
indicating that the decisive role of ligands. With the aim to 
transport in depth of tumor, multi-ligands or multi-functional 
ligands have been used to alternate the negative effects of 
mono-high ligand density. 
5. Conclusion and future prospect 
Since HCC is a complex multi-step process influenced by 
many factors for its initiation and progression, therapeutic in- 
terventions are challenging for this disease. With the rising in- 
cidence of HCC and high morbidity and mortality rates asso- 
ciated with this cancer, there is an urgent need to develop ef- 
fective treatment and prevention strategies. We have reviewed 
the various targeted receptors and recent treatment modali- 
ties of HCC with emphasis on nanotechnology strategies in 
the field of HCC. While surgical resection and liver transplan- 
tation are the only strategies available for treating advanced 
stage patients, nanomedicines and immunotherapy might be 
promising approach for successful treatment of HCC in the 
future. Not only safety, toxicity, preclinical efficacy studies 
are required thoroughly before any clinical application of 
these delivery strategies are further explored. As GWAS and 
more comprehensive data sets become available, the clinical 
advantages of using nanomedicine for HCC treatment might 
be better understood. Based on the personalized medicine, 
combined nanomedicines with immunotherapy would be a 
fine choice for HCC therapy. Immunotherapy strategies have 
exhibited encouraging results for various cancer therapies. 
However, the dynamic nature of immune responses at the 
HCC sites and some other challenging such as complication of 
multi-immune and individual difference would lead to com- 
bination nanotechnology and immunotherapy an opportunity 
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and challenge coexist in clinic. With the development of im- 
munotherapy, all together these will forecast a bright future 
of nanomedicine for hepatocellular carcinoma therapy when 
it could control and regulate the immune response from ex- 
ogenous immune stimulation. 
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